- Home
- HRTX vs CBIO Comparison
HRTX vs CBIO Comparison
Compare HRTX & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- CBIO
- Stock Information
- Founded
- HRTX 1983
- CBIO 2003
- Country
- HRTX United States
- CBIO United States
- Employees
- HRTX N/A
- CBIO N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- CBIO
- Sector
- HRTX Health Care
- CBIO
- Exchange
- HRTX Nasdaq
- CBIO Nasdaq
- Market Cap
- HRTX 276.1M
- CBIO 308.0M
- IPO Year
- HRTX 1987
- CBIO N/A
- Fundamental
- Price
- HRTX $1.35
- CBIO $14.29
- Analyst Decision
- HRTX Strong Buy
- CBIO Strong Buy
- Analyst Count
- HRTX 2
- CBIO 5
- Target Price
- HRTX $4.50
- CBIO $25.60
- AVG Volume (30 Days)
- HRTX 2.6M
- CBIO 97.6K
- Earning Date
- HRTX 08-08-2025
- CBIO 07-31-2025
- Dividend Yield
- HRTX N/A
- CBIO N/A
- EPS Growth
- HRTX N/A
- CBIO N/A
- EPS
- HRTX N/A
- CBIO N/A
- Revenue
- HRTX $149,694,000.00
- CBIO N/A
- Revenue This Year
- HRTX $10.62
- CBIO N/A
- Revenue Next Year
- HRTX $12.99
- CBIO N/A
- P/E Ratio
- HRTX N/A
- CBIO N/A
- Revenue Growth
- HRTX 9.78
- CBIO N/A
- 52 Week Low
- HRTX $1.04
- CBIO $10.83
- 52 Week High
- HRTX $2.68
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- HRTX 36.48
- CBIO 52.92
- Support Level
- HRTX $1.33
- CBIO $13.50
- Resistance Level
- HRTX $1.43
- CBIO $16.00
- Average True Range (ATR)
- HRTX 0.07
- CBIO 0.79
- MACD
- HRTX 0.02
- CBIO 0.16
- Stochastic Oscillator
- HRTX 45.45
- CBIO 39.68
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.